Impact of COVID-19 on UTI Management with iAluril Treatment Case Study

Changes in Bladder Instillation Practices for Female Patients

Are you in need of online assignment help in the UK with a free case study? Look no further than Native Assignment Help. We have a dedicated team of professionals committed to delivering customized support for your academic needs and ensuring you get excellent marks on all your assignments.

Introduction: Impact of COVID-19 on UTI Management with iAluril Treatment

The evaluation has been conducted in a setting of secondary care in the interest of minimising the risk of urinary tract infection that is happening in today's population among female patients. Before the pandemic of COVID-19, there had been some guidelines related to treating patients with recurrent urinary tract infection using bladder instillation iAluril. Moreover, as the progression occurs in a pandemic, there has been seen a huge impact on the delivery of services in benign urological conditions, especially bladder installation for urine tract infection. Many guidelines have been provided on international, local, and national levels to make people aware of their ongoing bladder installation treatments.

Intravesical bladder installation (iAluril) is a treatment that involves filling the bladder with some solution and leaving it in place for a specific period according to the manufacturer's guide. Although men are also affected with UTI, however, this installation process is dominant in females to treat the inflammation of the bladder lining and wall, and this is a common condition called cystitis (Jung and Brubaker, 2019). The main purpose of the installation of a bladder is to reduce inflammation and any sort of discomfort in the bladder, which helps to reduce these symptoms. It can be argued that reducing the symptoms automatically reduces the burden of suffering and avoids more complicated bladder issues, and that makes it a reliable solution.

After the COVID-19 pandemic, the scenario of recurrent UTIs and the self-administer bladder instillation have been changed. The maps of common urinary tract symptoms are mainly urgency, frequency and nocturnal. The urinary tract symptoms have increased in number after the pandemic of COVID- 19 (Murray et al. 2021). The COVID-19 pandemic has had a huge effect on the increasing number of urinary tract symptoms leading to urine infections. This study will focus on the self-administering iAluril treatment associated with UTIs and its effect before and after the 19th pandemic.

Recurrent urinary tract infection in Women

Urinary tract Infection is mainly caused by Escherichia coli, a type of bacteria that levies in the intentional system of people. In the case of carrying E.coli bacteria from the rectum to the vagina, the bacteria can also enter via the urethra. urethra is a tube that brings out urine from the bladder and infections occur within the bladder. The risk factors associated with UTI may vary with age. As told by Cai (2021), in women, before menopause, most of the common risk factors can be seen while using spermicides in case of sexual intercourse. These recurrent UTIs are a common disease that is mainly caused by the reinfection by the same pathogen. As highlighted by Storme et al. (2019), one of the major risks associated with recurrent UTIs is sexual intercourse. Recurrent urinary tract infections are one of the main causes of morbidity, mainly in the younger-aged woman. However, it can be cured with the appropriate care and these infections can be prevented further. Recurrent urinary tract infectionscan be defined as the episode of two “acute bacterial cystitis”.

Epidemiology

Approximately one in three women has always been suffering from complicated urinary tract infections before the age of 24. The total prevalence from the last year has been seen as symptomatic UTI, which has shown that women are estimating almost to be more than 50%. Of the 26%, the woman demonstrated recurrence related to six months and must have follow-up treatment related to recurrent urinary tract infections as the initial stages of treating UTI. A study of primary setting care has shown that almost 53% of women who are dealing with this disease are more than 55 years old, and similarly, 36% of the young woman are being reported to dealing with recurrent urinary tract infections within last 1 year. It has also determined that overall, there are so many uncomplicated cases of recurrent UTIs there are more than 102 cases that have happened per 100,000 women in general. Some of the incidents represented the rate of this disease among 105/100,000 women between the ages of 18 to 34 years. Some of 77 people, 100,00 women and age between 35 to 44 years have been seen. In ages between 45 to 54 years, there are seen 189/ 100,000 women have been seen (National Institute of Health, 2023). This case is higher frequencies in women.

Figure 1: Rate of Recurrent UTIs among women in the different age groups

Pathophysiology

The infectious disease "Recurrent Urinary tract infections" are mainly new types of infections that happen associated with new types of bacteria. The main source of recurrent Urinary tract infections is the same as the process of simple cystitis. Mainly, these bacteria can ascend to the bladder, and from here the responsible bacteria can be easily reach the bladder. Some of the research also shows that the disease has a complex relationship with the intestinal, urinary, and vaginal micro biome.

Non-antimicrobial treatment for UTI

"Urinary tract infections" (UTIs) is an infectious disease caused by bacteria, so mainly most doctors usually treat the disease with antibiotics. As proposed by Rodriguez-Mañas (2020), other than antibiotics, there are some non-antimicrobial treatments also present there, as well as some tips to manage the disease. Some of the ways of treating UTIs without using antibiotics include the following approaches that can be applied:.

Urinate if needed

Frequencies in urination can also help to flush the bacteria from the urinary tract. It can also be used to reduce the bacteria which are in the urine and that may be exposed to cells in the tract. As stated by Zachariou et al. (2022), this can also limit the risk of them attacking and infecting the cells. So more often urination can strike and can treat UTIs.

Use of Probiotics

Some of the beneficial bacteria, which are called probiotics, can help to keep the “urinary tract” free from harmful bacteria and healthy. More precisely, probiotics which are in the Lactobacillus group may help to treat and prevent UTIs. Probiotics help to prevent harmful bacteria from further attacking the cell of the urinary tract. These probiotics also help to produce hydrogen peroxide, which is a strong antibacterial agent; this can also help in preventing harmful bacteria in the urine (Wagenlehneret al. 2022). Including probiotics also can help with the lowering of pH in the urine; this condition makes the lower cause of bacteria. As a source of probiotics yoghurts, cheese, sauerkraut, and kefir can be added.

Include enough Vitamin C

Vitamin C is an antioxidant that helps to maintain the function of the Immune system. It also reacts with the nitrates present in urine and helps to kill bacteria, as well as helping to lower the pH of the urine and make a place less likely to live for bacteria (Jafari et al., 2019). However, it has been found that consuming more Vitamin C can help to treat and prevent UTIs.

Wipe from front to back

“Urinary tract Infection” can develop if the bacteria form a rectum in the urethra. This specific small channel can allow urine to pass through the body. Once bacteria form in the urethra, they can travel up to the “Urinary tract organs” and can cause the infection.So, it is necessary to wipe every time after urination, which helps to prevent the bacteria from moving from the anus to the genitals. It is also needed to use separate pieces of paper to wipe up to lower the infection rate.

Stay hydrated

Drinking enough water can prevent many diseases, and UTIs are one of them. Water helps to remove the waste from the urinary tract organs more effectively and at the same time retaining the body with electrolytes and vital nutrients. Staying hydrated also helps to dilute the urine which also speeds the journey from the system. It also makes the harder a path for bacteria to reach and infect the urinate cells which are lined in the urinary organs.

Service evaluation

Urinary tract Infection are classified as common infections; however they can get more critical if the proper medication is not provided immediately which can result in complicated urine infection.There are primary healthcare services related to UTIs. Primary care provision and using of other health care providers can also help to treat most of UTIs.

Antibiotics

Antibiotics are the first treatment that helps to treat in the infection of the urinary tract. Some of the common antibiotics are "Trimethoprim", "Sulfamethoxazole", “Nitrofurantoin", "cefalexin", "Amoxicillin,” and "Ceftriaxone," whichare usually helping to treat UTIs (British National Formulary, (BNF), 2023). As highlighted by Yang et al. (2023), these antibiotics include Ciprofloxacin, which helps to lower the risk, and drugs that generally used in the benefits to treat complicated UTIs. Antibiotics are the first and main treatment that can be given to patients with an infection in the urinary tract system.

The first-line oral antibacterial option for UTI is Nitrofurantoin or Trimethoprim if indicated to be low-risk of resistance (NICE, 2019). Although Sulfamethoxazole can be used in combination with Trimethoprim as Co-trimoxazole to treat UTIs, this should be used with caution and only if there is evidence of sensitivity to the drug and after consulting microbiology (BNF, 2023). This can be treated for UTI in just three days. For some people, it can take some more time. "Nitrofurantoin” is another choice to treat UTIs. “Fosfomycin" also can be useful for UTIs, which are caused by bacteria. It can help be a better single-dose treatment.

Figure 2: Number of Antibiotics used in Recurrent UTIs

Self-administering bladder installation

Idea of instillations of antibiotic bladder, some people are unable to tolerate the oral antibiotics that have been prescribed, for these patients this is a great alternative. Some of the results show that the installation of the bladder can vary. As opined by Cabas et al., (2021), a bladder installation is a process by which it can help to fill the bladder with a solution and also helps to leave it someplace (Chen et al. 2021). Then it helps in draining the solution by using the catheter. “Dimethyl Sulfoxide" is one of the solutions that help in the treatment of bladder infections. This can effectively ease the discomfort of the bladder. This also helps to relax the pelvic muscles of the bladder, thus helping to improve the capacity of the bladder.

Diagnosis

There are some tests and procedures to diagnose the infection related to “Urinary tract disease". Some groups of antibiotics known as "Fluoroquinolones” are commonly used to treat simple types of UTIs. But in case of complicated UTI or any type of infection in the kidney, some of the tips of healthcare can be provided. As said by Das (2020), for an uncomplicated UTI, it can be recommended a short course of treatment, which can take some antibiotics to treat enough for the treatment of diseases.

Alternative medicine

Some people take cranberry juice to prevent infection with UTIs. Some research shows that cranberry juice or tablets of cranberry helps to protect from UTIs, as the properties of cranberry can help to fight against the infectious bacteria of UTIs. There is some sort of simple sugar, "D-mannose.” This helps in the treatment of UTIs. This occurs in a natural way in various types of food, which can be included in apples, and cranberries This will help in the use of UTI therapy.

Healthcare Service

Other than all the medicine and supplements, expectations of UTIs can be cured by healthcare organizations. Thus, attempting the diagnosis can also help to treat the problem of UTIs.Some of the health care services can be taken in case of the complicated UTIs, which are needed to be checked in a process of healthcare. Some of the diagnosis in the healthcare is needed for that.

Aims

The main aim of the study is to evaluate and assess the success of "Self-administering installation" among patients with "Recurrent Urinary tract infection" (UTI), before COVID-19 and before the COVID-19 pandemic, and how this medical system brought some changes in the practice in the department of urology.

Objectives

The objective of the research paper includes

• To reduce the consumption of antibiotics, as well as a reduction in “antimicrobial resistance”.
• To deliver the best quality improvement in the treatment of patients and urology services.
• To encourage the patient to take “ownership of their health”.

Dissertation Summary

Figure 3: Dissertation structure

Literature Review

Source of the Databases and keywords

Table 1: Services of Database and keywords from the Boolean operator

Keywords

The keywords that have been used here while the search process include some words “Intravesivcal bladder instillations”, “Recurrent UTIs”, “Self-administering bladder instillations”, pre COVID- 19 pandemic, Post COVID- 19 pandemic. “Changes of practice”, “Prevention”, “invasion”, “treatment”, "Non-microbial treatment", "Antibiotic treatment" as well as “rate of success” are some of the keywords that have been taken.

Database

A comprehensive search for relevant literature was conducted using reliable academic databases; the Resource Finder and ProQuest Central database was undertaken using the keywords that related to the research question and objectives. The articles have been obtained from “PubMed”, “Google Scholar”, “Medline Plus” as well as included some literature. Those articles also have been chosen which are included some literature review and contain meta-analysis which is essential for the study.

Justification

The search process for these articles has been done by using the databases from the duration of time of the last 5 years. That means from (2019 to 2023) databases have followed only. Some databases such as “PubMed”, “Lancet”, “Google Scholar”, “Mayo Clinic" “And Medline Plus" have been taken for the review of the literature. This word includes words "Intravesical bladder instillations", "Self-administering bladder instillations" “Recurrent UTIs”, “Post COVID- 19 pandemic”, “pre COVID- 19 pandemic”, "Non-microbial treatment", "rate of success”, “Antibiotic treatment”. By using these terms some Meta-analyses have been done. Some of the Boolean operators have also been used. They are "AND", "OR", and "NOT". They are being used to conduct the process of search. The criteria of the search in this specific study are mainly limited to the patients who are dealing with "UTIs" among females.

This database uses to find medical information related to the topic of "recurrent of Urinary tract Infection". This database has played a vital role in the assessment of the topic. Keywords are the common term, which has been used here to search the terms, to enter the box of the database. The main significance of using this database is to describe the topic and it will be more effective to describe the topic by using the database. Without applying the right keywords, it will get difficult to find the major issues and information related to this topic. So, keywords play a more vital role in the search process.

The reviewing literature aims to give an overview of the critical evaluation of the topics which already exist. The literature review aims to mainly identify the main findings and theories and synthesize them. As said by Andretta et al. (2022), “Intravesical Gentamicin Instillations" refer to being safe as this is an effective method in the treatment of "Recurrent Urinary Tract Infections". Patients having UTIs performed in the "intermittent catheterization". From the above research paper, it has been found that this therapy is very effective in the case of alternative therapy in the treatment of UTI. This instillation treatment is applicable for patients who are having UTIs shows few complications that can be shown the effect in long term. Similarly, it is also said by Stalenhoefet al. (2019), UTIs can be also treated with the antimicrobial treatment, for a duration of 7 days and it also helps patients to deal with the infections with UTIs. However, some limitations can also be seen in the case of the diagnosis of the UTIs. Nevertheless, it can be confirmed that an alternative diagnosis also can be made in the case of "Urinary tract Infection".

Self-administration of Bladder instillations is an important invasion in case of UTIs. It is suggested by Mitchell et al. (2023), that bladder instillations are the combination of therapy of drugs that helps to people ease in their pain and in the painful bladder that often occurs as a cystitis type symptom and reduces recurrent UTIs. It was agreedbyNabeehet al. (2022), that the bladder instillation treatment helps to the installation helps the minimisation of bacterial infection to constantly damaging the bladder lining. The installations of the bladder help to reduce inflammation and also help with the bladder which further helps to ease the symptoms. But in the contrast, it has also been told by Larsen et al., (2021), that there are also some issues related to the installation of the bladder. It can be argued that not everyone might not experience the effects of the bladder installations, however, but some of the patients can observe an increase in the frequency of the urinary, also causing the discomfort when passing urine (Wilson et al., 2022). The discomfort can also be caused by the catheter which is used to drain the urine first prior to instillation.These side effects are mostly variable from the other symptoms. But to ease discomfort, some of the medicine such as paracetamol, can be used.

To maintain the infectious disease some of the management related to UTIs have been taken also in the time of the COVID-19 pandemic. As it is proposed by Tariganet al. (2023), in case of some cases related to UTIs it has been seen some "empirical antimicrobial treatment" can be occurred with the help of the guidelines of internationally. Some bacteria with asymptomatic are not a risk factor in patients who are affected by COVID-19. This management of the risk factors related to COVID-19 can be maintained. It has also been stated by Moussa et al. (2021), the most common disease that occurs in females is mostly caused by lower urinary tract symptoms which can also increase the severity risk of the infection during the COVID-19 pandemic. The effects of COVID-19 can also have a significance that can also increase the lower tract system.Furthermore, it has been observed that the problems with the urinary tract infection can increase the presence of the bacteria in the position of infection which can also be led to the viral invasion.

Reviewing the Literature

“Bladder pain syndrome” is effectively characterised by bladder discomfort which is associated with urinary infection. As referred by Abdel-Fattah et al. (2021), frequent urinary has been effectively diagnosed by the effectiveness that leads to the development of an overactive bladder that commences with recurrent UTI. The data extracted from the results reveal that bladder pain is associated with the development of urinary tract infection. The components that are linked with the pathogenesis have propagated the urothelium/transitional epithelium which acts as the protective layer that leads to the development of urothelial cells. This cell receptor is chondroitin sulfate (CS), “actively hyaluronic acid” (HA), “dermatansulfate”, heparin sulfate, and keratin sulfate. On the contrary, as suggested by Broncano-Lavadoet al. (2021), urinary infection is often associated with the development of the addition of Intravesical therapies with conjugation in developing a technique using psychotherapies. The information gathered from the findings reveals that the application of Intravesical therapies results in replenishing the GAG layer deficient. It leads to altering hypersensitivity and neurogenic inflammation. Therefore, from this critical evaluation, it is determined that “bladder pain syndrome” is characterised by a urinary infection. Intravesical therapies are an effective technique using psychotherapies which helps in replenishing GAG layer deficiency.

Intravesical therapies promote altering hypersensitivity and neurogenic inflammation. As opined by Suhet al. (2022), different therapies have been identified which prominently able to treat “bladder pain syndrome”. Dimethyl sulfoxide solvent has been prominently used and therefore approved by “United States Food and Drug Administration”. The data extracted from the discussion of the following article reflect that this therapy has been successfully implemented into the clinical effort for its facilitating detrusor relaxation,acting as an analgesicand reducing inflammation, therefore, it is evident that Intravesical therapies that have been provided to the individual suffering from “bladder pain syndrome” helps in instillation regimens. However, according to Byron, (2019), the instillation process is a long way procedure that is actively used among patients suffering from the effective and bladder syndrome has helped in developing treatment processes. The information gathered from the result section of the following article reflects that instillation after 4 weeks required a repetitive instillation for up to four weeks for persistent symptoms possible. To investigate the symptoms associated with urodynamics, a placebo-controlled trial has been done with 33 patients using dimethyl sulfoxide(DMSO). It is determined that higher objective observed to be 35% vs. 93% and subjective observed to be 18% vs. 53% improvement. Henceforth, from this critical evaluation, it is determined that DMSO has been effective involve in developing and effective in reducing frequent urine and pain.

DMSO has been a powerful therapy for analysing the affective implication on the ground at which the assessment needs to be processed. As mentioned by Colemeadow et al., (2020), the evaluation of Intravesical therapies using DMSO performed in a randomised, double-blind crossover study has been compared to delivering therapy DMSO to” intravesical “bladder pain syndrome” among 21 patients. The findings obtained from each of the patient groups underwent six weekly instillations which crossed over other treatments, revealing no significant data of improvement. In this investigation, patients have been effectively assessed to symptom-related questionnaires, voiding diaries, and a VAS pain scale. It is revealed that no improvement has been measured during the resulting outcome in bladder pain syndrome. Similarly, as stated by Derbyshire and Pearce, (2021), different series of cocktail has been identified that promptly allow the association of the instillation of DMSO on a weekly basis. The information gathered from the discussion reveals that the administration of the cocktail of DMSO among the 25 patients has been measured to be effective with an initial remission of 92%. The data reported that relapse instillation therapy has been found in patients with a “lower response rate”. Therefore, from this critique, it can be summarised that DMASO and its cocktail instillation in “bladder pain syndrome” has a significant difference in terms of the “lower response rate”.

Heparin has been evident according to the theoretical action that involves replenishing urothelial GAG layer. The mode of action that is identified is inhibits fibroblast proliferation, anti-inflammatory and promotes angiogenesis and smooth muscle cell proliferation. As referred by Digesu et al., (2020), lidocaine has been actively used in single-agent instillation used in common with the heparin combination. The data extracted from the result section reveal that the formulation and concentrations with the alkalising agent combination avoid ionisation within the urine and to better penetrate the urothelium. “Single-agent alkalised lidocaine” has been investigated using “double-blind placebo-controlled” revealing that the initial improvement observed is followed by a reduction after 15 days. On the other hand, as suggested by Aranagaet al. (2022), the multi-therapy agent has been effectively found to be used with heparin, an intravesical therapy showed immediate pain relief after 1 instillation frequency, it is observed to be higher in group 2 as compared to group 1 which reflect “94% vs. 75%; P<0.01”. The information obtained from the “twenty patients in group 2” underwent has been incorporated with “6 instillations over 2 weeks”. This tends to show 80% “symptom relief persists” that lasts for 48 hours. Therefore, from this critical evaluation, it is determined that lidocaine with heparin involves “inhibits fibroblast proliferation”, is anti-inflammatory and “promotes angiogenesis” and “smooth muscle cell proliferation”. However, the treatment with this does not last for long.

Bladder pain syndrome is effectively characterised by bladder discomfort which is associated with urinary infection. As opined by Abdel-Fattah et al. (2021), frequent urinary has been effectively diagnosed by the effectiveness that leads to the development of an overactive bladder that commences with recurrent UTI. Intravesical therapies promote altering hypersensitivity and neurogenic inflammation. Pentosanpolysulfate sodium is one of the therapies that have been identified which is prominently able to treat “bladder pain syndrome”. PPS has been approved by the FDA for treating BPS/IC. This therapy's implication helps in “restoring the GAG layer” in BPS/IC treatment. PPS inhibits histamine that releases “mast cells and reduces” bladder “intracellular calcium ion levels”. The disadvantage is associated with “low urine concentrations” resulting in a “lag time of up to 6 months”. Clinical improvement using this is highly observed. On the contrary, as referred by Broncano-Lavadoet al. (2021), “Intravesical therapy” has the “theoretical advantage” of achieving a more “rapid response” to PPS treatment. The information gathered from the intravesical placebo treatment with 41 patients on instilling using PPS shows a significantly greater reduction which promotes Health-related quality with the “improvement in the treatment group”. Hence, this critical evaluation of the evidence suggests that PPS has been effectively used in the “treatment of BPS/IC” in “restoring the GAG layer”.

Sodium hyaluronate has been used to replenish deficiencies in the GAG layer. As suggested by Tangpaitoon and Swatesutipun(2023), it is involved in biological activities which include increasing healing of “connective tissue” and leukocyte migration inhibition and aggregation in BPS/IC patients. The data extracted from the studies reveal that treatment with a Sodium hyaluronateregimen with four weekly consist installations until the patient's symptoms have been resolved. Similarly, as opined by Maffucciet al. (2023), HAefficacy in 126 patients in the “first-line therapy” has been identified. HA weekly installations have been given to patients who are “significantly improved” or “symptom-free”. The data extracted from the article findings section reveal that assessment during post-Covid-19 using a “non-standardised questionnaire” using a “VAS symptom score” reveals the effect on “quality of life” related questions undergoing “repeat instillation therapy”. It is obtained findings and interpreted that “Eighty-four per cent” reported enhancing the quality of life with 86% that repeat “HA treatment”. “Thirty-four per cent” had a recurrence of symptoms which is further required for installations. Therefore, from this critical evaluation, it is determined that Sodium hyaluronate is involved in biological activities which include increasing healing of “connective tissue” and leukocyte migration inhibition and aggregation in BPS/IC patients.

In “Non-muscle-invasive bladder cancer” (NMIBC) patients, “adjuvant intravesical therapy” used in the form of “bladder pain syndrome” instillations or chemotherapy is advocated to “optimize disease control”. However, as opined by Zeitouniet al. (2021), a repeat visit during a pandemic increases the threat of infecting viral attacks. It is evident that the Covid-19 mortality rate has been reported to increase with significant age that ranges from “0.32% in 20–49-year” age group to “14.8% in ≥ 80-year” age group. According to Bowyer et al. (2022), the influence of lifestyle changes has been evident in increasing bladder cancer which tends to develop as a chronic condition with a “median age of over 70 years”. It is highly prone to severe sequelae. It leads to an increase in the contract of Covid-19. The issue is significantly identified within “continue, postpone, or terminate” intravesical therapy among NMIBC patients leading to generating a poll question. As mentioned by Sarfrazet al. (2022), polling questions have been posted on the digital platform with the dominant pReferences that possibly draft the need for the change in the intervention plan with a wide “resource availability” and “changing pandemic situation”.

“Intravesical chemotherapy” and “repeated instillations” have shown effective improvement in the recurrence rate in “intermediate-risk NMIBC”. As stated by Dubinskayaet al. (2022), the regimens at different centres refer to the installation number and treatment course duration. A “short intensive schedule” within the “first 3–4 months” in a long term with a “1-year course”the less “intensive treatment schedule” needs to appear with equal effectiveness. The oncological study results imply the safe incorporation of “intravesical chemotherapy instillations”. Longer treatment duration has been planned. However, patients undergo frequent hospitalisation despite a less “frequent instillation schedule”. It prominently leads to an increase in the risk of “Covid-19 infection” and must be “weighed against the benefit” of a 38% reduction in the “1-year recurrence rate”. Therefore, patients who undergo “intravesical chemotherapy” need to follow “surveillance cystoscopy”.

For intravesical“bladder pain syndrome” therapy, the induction requires “6-weekly installations”, which is followed by “1–3 years of maintenance course” for “intermediate to high-risk NMIBC”. As stated by Zaldastanishviliet al. (2021), It is evident through the instillation process, to four-to-six weekly instillations are prominently required to achieve a “maximum immune-response level”. The rationale of the induction regimen has been evident. The result demonstrated at least “1 year of maintenance” “bladder pain syndrome” by “superiority over mitomycin C”. However, as mentioned by Suhet al. (2022), high-risk NMIBC patients, have highly benefited from “bladder pain syndrome” for better “cancer control outweighs” the Covid-19 potential risk associated with infection with the treatment course. Therefore, to minimise the hospital number of visits, the induction course is effectively required for at least “four out of six doses” and “two out of three doses” of “maintenance acceptable course”.

Methodology

Design

The study design is the one-way pattern of writing a methodology. As opined by Suhet al. (2022), in retrospective studies, the outcome of interest occurred taking population was exposed by enrolling their individual . In this design, data has been collected by collecting historical data from patients notes in regard to the events of exposures. There is no follow-up of participants. According to Olin et al. (2022), a retrospective study has been investigating the specified outcomes at the study during the beginning of data collection by looking backwards at previous patients. Descriptive analysis of the retrospective audit allows the patients to be enrolled after showing exposure and interest in the clinical event that is highly conducted by review of the medical notes. A descriptive design has been used for this study as it helps in analysing the overall recruitment, data collection and interpretation process.

Justification

Bladder pain syndrome is effectively characterised by bladder discomfort which is associated with urinary infection. As referred by Scarneciu et al., (2021), frequent urination has been effectively diagnosed by the effectiveness that leads to the development of an overactive bladder that commences with recurrent UTI. The data extracted from the result reveal that bladder pain is associated with the development of urinary tract infection. There is no follow-up of participants. A retrospective study has been investigating the specified outcomes at the study during the beginning of data collection by looking backwards at previous patients. Descriptive analysis of the retrospective audit allows the patients to be enrolled after showing exposure and interest in the clinical event that is highly conducted by reviewing of the medical notes. A descriptive design has been used for this study. It helps in analysing the overall recruitment, data collection and interpretation process. The components that are linked with the pathogenesis have propagated the urothelium/transitional epithelium which acts as the protective layer that is promising leads to the development of urothelial cells. On the contrary, as suggested by Tsai et al. (2021), urinary infection is often associated with the development of the addition of Intravesical therapies with conjugation in developing a technique using psychotherapies. The information gathered from the findings reveals that the application of Intravesical therapies results in replenishing the GAG layer deficient. It leads to altering hypersensitivity and neurogenic inflammation. Therefore, from this critical evaluation, it is determined that “bladder pain syndrome” is characterised by a urinary infection. Intravesical therapies are an effective technique using psychotherapies which helps in replenishing GAG layer deficiency.

Recruitment

The recruitment process has been initiated by analysing the eligibility criteria. The patients are recruited based onpatient undertaking intravesical bladder therapies. Following permission from gatekeepers, records and notes of patients’ meeting eligible criteria have been recovered from the medical records. Two sets of the patients have been recruited, one patient group has been treated for recurrent UTI with iAlurilbladder instillation between June 2019 and January 2020, thiswas pre covid-19. The second set has been recruited with the patients being treated for recurrent UTI between April 2022 and October 2022 however this group were self-administering bladder instillation (iAluril) and this was referred to as post-Covid-19. The risk associated with “bladder pain syndrome” therapy leads to developing an effective strategy that emphasizes the oncological data lack. “bladder pain syndrome” shortage within countries has been provided with alternative treatments which include “device-assisted intravesical chemotherapy”, therefore, “bladder pain syndrome” vaccination appears to be less efficient in “lower incidence and death rate” within Countries from Covid-19.

Justification

Intravesical therapies promote altering hypersensitivity and neurogenic inflammation. As mentioned by Singh et al. (2021), different therapies have been identified which prominently able to treat bladder pain syndrome. Dimethyl sulfoxide solvent has been prominently used and therefore approved by “United States Food and Drug Administration”. The data extracted from the discussion of the following article reflect that this therapy has been successfully implemented into the clinical effort for its facilitating of detrusor relaxation, acting as an analgesicand reducing inflammation.Therefore, it is evident that Intravesical therapies that have been provided to the individuals suffering from bladder pain syndrome ininstillation regimens. However, as stated by Zaldastanishviliet al. (2021), the instillation process is a long way procedure that is actively used among patients suffering from the effective and dramatic syndrome and has helped in developing treatment processes.

Sampling

Sampling is the technique of taking samples among the population and the group. As referred by Nickel (2022), the sampling technique has been effectively used for its effectiveness that subsequently, bladder pain syndrome is characterised by bladder discomfort which is associated with urinary infection. As opined by Abdel-Fattah et al. (2021), frequent urinary has been diagnosed by the effectiveness that leads to the development of an overactive bladder that commences with recurrent UTI. Therefore, a systematic sampling technique has been used in this retrospective audit study. This study enables to review of the sample with a targeted database. The target population has been recorded through a primary method which helps in determining with the help of statistical analysis by calculating the sample size.

Justification

Intravesical therapies promote altering hypersensitivity and neurogenic inflammation. Pentosanpolysulfate sodium is one of the therapies that have been identified which is prominently able to treat bladder pain syndrome. As opined by Lovasz(2019), to evaluate and minimize the risk of Covid-19 infection, patients, and healthcare professionals must be reminded to practice stringent hygienic measures including wearing masking and hand washing frequently in the hospital. Intravesical instillations within single rooms are possible with adequate “distance between patients’ beds. Healthcare professionals should wear personal protective equipmentwhile delivering intravesical therapy. As suggested by Mareiet al. (2021), a retrospective study has effectively been used which tremendously helps in developing and effectively and propagating the synthesis. This study enables to review of the sample with a targeted database. The target population has been recorded through a primary method which helps in determining with the help of statistical analysis by calculating the sample size.

Are you struggling with your healthcare assignment help? Native Assignment Help provides expert assistance to ensure top grades. Our expert writers deliver good-quality, plagiarism-free content according to your needs. Trust us to be your partner and excel in your academics.

Reference list

Abdel-Fattah, M., Chapple, C., Guerrero, K., Dixon, S., Cotterill, N., Ward, K., Hashim, H., Monga, A., Brown, K., Drake, M.J. and Gammie, A., (2021). Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.Trials,No.22, pp.1-18.

Andretta, E., Longo, R., Balladelli, M., Sgarabotto, C. and Sgarabotto, D., (2022). Intravesical Gentamicin: An Option for Therapy and Prophylaxis against Recurrent UTIs and Resistant Bacteria in Neurogenic Bladder Patients on Intermittent Catheterization.Antibiotics,Vol.11, No.10, p.1335.

Anger, J., Lee, U., Ackerman, A.L., Chou, R., Chughtai, B., Clemens, J.Q., Hickling, D., Kapoor, A., Kenton, K.S., Kaufman, M.R. and Rondanina, M.A., (2019). Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline.The Journal of urology, Vol.202, No.2, pp.282-289.

Aranaga, C., Pantoja, L.D., Martínez, E.A. and Falco, A., (2022). Phage therapy in the era of multidrug resistance in bacteria: A systematic review.International Journal of Molecular Sciences, Vol.23, No.9, p.4577.

Bowyer, G.S., Loudon, K.W., Suchanek, O. and Clatworthy, M.R., (2022). Tissue Immunity in the Bladder.Annual Review of Immunology,Vol.40, pp.499-523.

Broncano-Lavado, A., Santamaría-Corral, G., Esteban, J. and García-Quintanilla, M., (2021). Advances in bacteriophage therapy against relevant multidrug-resistant pathogens.Antibiotics,Vol.10, No.6, p.672.

Byron, J.K., (2019). Urinary tract infection.Veterinary Clinics: Small Animal Practice,49(2), pp.211-221.. Urinary tract infection.Veterinary Clinics: Small Animal Practice,49(2), pp.211-221.

Cabas, P., Rizzo, M., Giuffrè, M., Antonello, R.M., Trombetta, C., Luzzati, R., Liguori, G. and Di Bella, S., (2021), February. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review. InUrologic Oncology: Seminars and Original Investigations(Vol. 39, No. 2, pp. 85-92). Elsevier.

Cai, T., 2021. Recurrent uncomplicated urinary tract infections: definitions and risk factors.GMS infectious diseases,9.

Chen, Y.C., Liang, Y.C., Ho, S.J., Chen, H.W., Juan, Y.S., Tsai, W.C., Huang, S.P., Lee, J.T., Liu, Y.P., Kao, C.Y. and Lin, Y.K., (2022). Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms?.Journal of Clinical Medicine,Vol.11, No.10, p.2736.

Colemeadow, J., Sahai, A. and Malde, S., (2020). Clinical management of bladder pain syndrome/interstitial cystitis: a review on current recommendations and emerging treatment options.Research and reports in urology, pp.331-343.

Das, S., (2020). Natural therapeutics for urinary tract infections—a review.Future Journal of Pharmaceutical Sciences, No.6, pp.1-13.

Derbyshire, L. and Pearce, I., (2021). Bladder pain syndrome.Obstetrics, Gynaecology & Reproductive Medicine,31(8), pp.225-231.

Digesu, G.A., Tailor, V., Bhide, A.A. and Khullar, V., (2020). The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?.International urogynecology journal,31, pp.1387-1392.

Dubinskaya, A., Tholemeier, L.N., Erickson, T., De Hoedt, A.M., Barbour, K.E., Kim, J., Freedland, S.J. and Anger, J.T., (2022). Prevalence of Overactive Bladder Symptoms Among Women with Interstitial Cystitis/Bladder Pain Syndrome.Female Pelvic Medicine & Reconstructive Surgery,Vol.28, No.3,pp.e115-e119.

Forde, B.M., Roberts, L.W., Phan, M.D., Peters, K.M., Fleming, B.A., Russell, C.W., Lenherr, S.M., Myers, J.B., Barker, A.P., Fisher, M.A. and Chong, T.M., (2019). Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection.Nature communications,Vol.10, No.1, p.3643.

Jafari, D., Esmaeilzadeh, A., Mohammadi-Kordkhayli, M., and Rezaei, N. (2019). Vitamin C and the immune system.Nutrition and immunity, 81-102.

Jung, C. and Brubaker, L., 2019. The etiology and management of recurrent urinary tract infections in postmenopausal women.Climacteric,22(3), pp.242-249.

Larsen, T.A., Riechmann, M.E. and Udert, K.M., (2021). State of the art of urine treatment technologies: A critical review.Water Research X,13, p.100114.

Lovasz, S., (2019). Minimally invasive device for intravesical instillation by urological syringe adapter (MID?ii USA) for catheter?free instillation therapy of the bladder in interstitial cystitis/bladder pain syndrome.International Journal of Urology,No.26, pp.57-60.

Maffucci, F., Chang, C., Simhan, J. and Cohn, J.A., (2023). Is There Any Benefit to the Use of Antibiotics with Indwelling Catheters after Urologic Surgery in Adults.Antibiotics,Vol.12, No.1, p.156.

Marei, M.M., Jackson, R. and Keene, D.J., (2021). Intravesical gentamicin instillation for the treatment and prevention of urinary tract infections in complex paediatric urology patients: evidence for safety and efficacy.Journal of Pediatric Urology, Vol.17, No.1, pp.65-e1.

Mitchell, B.G., Stewardson, A.J., Kerr, L., Ferguson, J., Curtis, S., Busija, L., Lydeamore, M., Graham, K. and Russo, P.L., (2023). The incidence of positive bloodstream and urine cultures in five Australian hospitals during the COVID-19 pandemic.

Moussa, M., Chakra, M.A., Papatsoris, A.G., Dellis, A., Dabboucy, B. and Fares, Y., (2021). Bladder irrigation with povidone?iodine prevent recurrent urinary tract infections in neurogenic bladder patients on clean intermittent catheterization.Neurourology and Urodynamics,Vol.40, No. (2), pp.672-679.

Murray, B.O., Flores, C., Williams, C., Flusberg, D.A., Marr, E.E., Kwiatkowska, K.M., Charest, J.L., Isenberg, B.C. and Rohn, J.L., (2021). Recurrent urinary tract infection: a mystery in search of better model systems.Frontiers in Cellular and Infection Microbiology,No.11, p.691210.

Nabeeh, H., Ibrahim, A., Taha, D.E., Talaat, M. and Abdelbaky, T.M., (2022). Impact of COVID?19 pandemic on lower urinary tract symptoms in patients with benign prostatic hyperplasia and predictors of urine retention in such patients.LUTS: Lower Urinary Tract Symptoms,Vol.14, No.1, pp.41-46.

Neugent, M.L., Hulyalkar, N.V., Nguyen, V.H., Zimmern, P.E. and De Nisco, N.J., (2020). Advances in understanding the human urinary microbiome and its potential role in urinary tract infection.MBio, Vol.11, No.2, pp.e00218-20.

Nickel, J.C., (2022). Managing interstitial cystitis/bladder pain syndrome in the female: clinical recipes for success.Canadian Urological Association Journal,Vol.16, No.12, pp.393-8.

Rodriguez-Mañas, L., (2020). Urinary tract infections in the elderly: a review of disease characteristics and current treatment options.Drugs in context,9.

Sarfraz, M., Qamar, S., Rehman, M.U., Tahir, M.A., Ijaz, M., Ahsan, A., Asim, M.H. and Nazir, I., (2022). Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases.Pharmaceutics,Vol.14, No.9, p.1909.

Scarneciu, I., Lupu, S., Bratu, O.G., Teodorescu, A., Maxim, L.S., Brinza, A., Laculiceanu, A.G., Rotaru, R.M., Lupu, A.M. and Scarneciu, C.C., (2021). Overactive bladder: A review and update.Experimental and Therapeutic Medicine,22(6), pp.1-8.

Stalenhoef, J.E., van Nieuwkoop, C., Menken, P.H., Bernards, S.T., Elzevier, H.W. and van Dissel, J.T., (2019), Intravesical gentamicin treatment for recurrent urinary tract infections caused by multidrug resistant bacteria.The Journal of urology,Vol.201, No.3, pp.549-555.

Storme, O., Tirán Saucedo, J., Garcia-Mora, A., Dehesa-Dávila, M., and Naber, K. G. (2019). Risk factors and predisposing conditions for urinary tract infection.Therapeutic advances in urology,11, 1756287218814382.

Suh, G.A., Lodise, T.P., Tamma, P.D., Knisely, J.M., Alexander, J., Aslam, S., Barton, K.D., Bizzell, E., Totten, K.M., Campbell, J.L. and Chan, B.K., (2022), Considerations for the use of phage therapy in clinical practice.Antimicrobial agents and chemotherapy,Vol.66, No.3,pp.e02071-21.

Tangpaitoon, T. and Swatesutipun, V., (2023), Factors associated with low-compliance bladder in end-stage renal disease patients and development of a clinical prediction model for urodynamic evaluation: the DUDi score.International

Tarigan, S.W., (2023), The Relationship between the Implementation of Urine Foley Catheter Installation and the Occurrence of Urinary Tract Infections in Inpatients at EfarinaEtahamBerastagi Hospital, Karo Regency.International Journal of Public Health Excellence (IJPHE),Vol.2, No.(2), pp.524-527.

Tsai, C.P., Yang, J.M., Liang, S.J., Lin, Y.H., Huang, W.C., Lin, T.Y., Hsu, C.S., Chuang, F.C. and Hung, M.J., (2021), Factors associated with treatment outcomes after intravesical hyaluronic acid therapy in women with refractory interstitial cystitis: a prospective, multicenter study.Journal of the Chinese Medical Association,Vol.84, No.4, pp.418-422.

Wagenlehner, F., Nicolle, L., Bartoletti, R., Gales, A.C., Grigoryan, L., Huang, H., Hooton, T., Lopardo, G., Naber, K., Poojary, A. and Stapleton, A., (2022). A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance.Journal of global antimicrobial resistance,Vol.28, pp.18-29.

Wilson, J., Farrow, E., and Holden, C. (2022). Urinary tract obstruction.InnovAiT,15(5), 265-271.

Yang, J., Eyre, D.W. and Clifton, D.A., (2023). Interpretable Machine Learning-based Decision Support for Prediction of Antibiotic Resistance for Complicated Urinary Tract Infections.medRxiv, pp.2023-01.

Zachariou, A., Sapouna, V., Kaltsas, A., Dimitriadis, F., Douvli, E., Champilomatis, I., Kounavou, C., Papatsoris, A., Tsounapi, P., Takenaka, A. and Sofikitis, N., (2022). Evaluation of overactive bladder symptoms in patients recovering from post-acute COVID-19 syndrome.Journal of Multidisciplinary Healthcare, pp.2447-2452.

Zaldastanishvili, E., Leshkasheli, L., Dadiani, M., Nadareishvili, L., Askilashvili, L., Kvatadze, N., Goderdzishvili, M., Kutateladze, M. and Balarjishvili, N., (2021). Phage therapy experience at the eliava phage therapy center: Three cases of bacterial persistence.Viruses,Vol.13, No.10, p.1901.

Zeitouni, L., Rahman, M., O’Hare, K., Warren, H., Pinto, T. and Hammadeh, M.Y., (2021), Multifocal bladder nephrogenic adenoma following repeated intravesical OnabotulinumtoxinA (Botox®) injection for refractory overactive bladder. Case report and literature review.Journal of Clinical Urology, p.20514158211025915.

Ziadeh, T., Chebel, R., Labaki, C., Saliba, G. and Helou, E.E., (2022). Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review.Urologia Journal,89(2), pp.261-267.